Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Vir Biotechnology has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $9.7 million for Q1 2023.

• Other Accumulated Expenses for Q1 2023 came in at $9.7 million, down 44.62% year-over-year; the trailing twelve-month figure through Mar 2023 was $9.7 million (down 44.62% YoY), and the FY2022 annual result was $12.7 million, up 23.96% from the prior year.
• Other Accumulated Expenses came in at $9.7 million for Q1 2023 at Vir Biotechnology, down from $12.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $21.4 million in Q3 2022 to a low of $595000.0 in Q2 2020.
• The 5-year median for Other Accumulated Expenses is $3.3 million (2021), against an average of $7.0 million.
• Across the five-year window, Other Accumulated Expenses plunged 56.53% in 2019 and jumped 1173.79% in 2021, its largest moves.
• Vir Biotechnology's Other Accumulated Expenses stood at $1.2 million in 2019, then sank by 30.36% to $805000.0 in 2020, then surged by 1173.79% to $10.3 million in 2021, then gained by 23.96% to $12.7 million in 2022, then decreased by 23.53% to $9.7 million in 2023.
• The last three Other Accumulated Expenses figures came in at $9.7 million (Q1 2023), $12.7 million (Q4 2022), and $21.4 million (Q3 2022), per Business Quant data.